High Grade Glioma (HGG) of the Brain With BRAF Aberration

Clinical trial pipeline · Data from ClinicalTrials.gov

See which High Grade Glioma (HGG) of the Brain With BRAF Aberration trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingEarly Phase 1

NCT07210632

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown…

United States38 participantsStarted 2026-03-30

Treatment: Nivolumab, Nivolumab-IRDye800

All recent trials (3 shown)

Not Yet RecruitingPhase 2

NCT07206849

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

The goal of this study is to determine the efficacy of the study drugs tovorafenib to treat pediatric and young adult patients newly diagnosed with a high-grade…

Location not specified79 participantsStarted 2026-05

Treatment: Tovorafenib

Active — Not RecruitingPhase 1/2

NCT04201457

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children wit…

United States57 participantsStarted 2020-01-17

Treatment: Dabrafenib, Trametinib